REVOLUTION Medicines Inc (RVMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$210.02-0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage operating expenses within $1.7 to $1.8 billion in 2026: OpEx guidance $2.1B-$2.2B vs $1.8B target.
Revolution Medicines is advancing cancer drugs with strong trial results. They plan $1.7 to $1.8 billion in expenses for 2026. The company raised $500 million with convertible notes. These moves support future growth and drug development.
The company keeps losing money and burning cash. Operating losses grew to $445 million in early 2026. Cash flow from operations is negative and worsening. Valuation concerns may hurt investor confidence.
The price is about 5% above our fair value near $182. The market expects slow growth and ongoing losses. Our view aligns with Street estimates.
Breaks if: Failure to maintain capital or repay convertible notes
Breaks if: Cash flow from operations falls below -$354 million next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given the company's focus on advancing clinical developments in oncology. The current thesis state indicates a watchful approach due to recent volatility and weak financial performance.
The market appears to have low expectations for RVMD, as indicated by its loss-making status and recent declines in company quality and management scores. There is a sense of fragility, but no immediate concerns are priced in.
Fundamentals may remain weak in the near term, especially with a 60% probability of an earnings miss looming. Management is focused on advancing clinical trials and commercialization, but recent performance has not met industry standards.
The thesis hinges on several factors, including the outcome of ongoing clinical trials, potential guidance changes in upcoming earnings calls, and the overall health of the healthcare sector. Positive developments from larger sector players could also influence RVMD's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company received full FDA approval for daraxonrasib. Analysts now estimate $11.5 billion in peak sales for this drug. However, the latest earnings report showed a significant miss. This miss raises concerns about future performance and guidance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating expenses exceed $1.8 billion in FY26
In the next 1 to 3 years, RVMD faces significant challenges but has potential if clinical advancements succeed. Not investment advice.